<DOC>
	<DOCNO>NCT00005609</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness rituximab treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Rituximab Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate previously treat previously untreated patient Waldenstrom 's macroglobulinemia receiving rituximab . II . Determine associated toxicity treatment , specifically frequency febrile hypotensive event , patient population . OUTLINE : Patients stratify accord prior treatment ( yes v ) . Patients prior treatment stratify accord type treatment ( alkylating agent vs purine nucleoside analogue ) . Patients receive rituximab IV 4 hour day 1 , 8 , 15 , 22 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 66 patient ( 33 per stratum ) accrue study within 36 month .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Waldenstrom 's macroglobulinemia confirm follow : Bone marrow lymphoplasmacytosis : Greater 10 % lymphoplasmacytic cell OR Aggregates , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy AND Measurable disease define quantitative IgM monoclonal protein great 1,000 mg/dL Bone marrow lymphoplasmacytosis beta2 microglobulin serum consider measurable Impaired bone marrow function due infiltration lymphoplasmacytic lymphoma Hemoglobin le 11 g/dL OR Serum viscosity level relative water great 4.0 Symptomatic clinically significant anemia ( le 11 g/dL ) , bulky lymphadenopathy symptomatic , symptom attributable hyperviscosity ( e.g. , nose bleeding , gingival bleeding , retinal hemorrhage ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : SGOT le 3 time upper limit normal Bilirubin le 2.0 mg/dL Renal : Creatinine great 3.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No significant arrhythmia within past 3 month Hypertension allow provide control medication Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Concurrent reversible complication ( e.g. , hyperuricemia , hyperviscosity ) allow provide therapy complication initiate complication subside Other prior malignancy allow provide curatively treat currently disease free PRIOR CONCURRENT THERAPY : No 2 prior regimen allow Prior tandem transplant consider 2 prior regimen Chemotherapy prior bone marrow transplantation part induction consider 1 prior regimen Retreatment regimen ( e.g. , repeat alkylating agent ) consider 1 prior regimen Biologic therapy : No prior antiCD20 therapy At least 1 month since prior epoetin alfa No concurrent epoetin alfa 2 month registration Chemotherapy : At least 28 day since prior alkylating agent At least 28 day since prior purine nucleoside analogue Endocrine therapy : At least 28 day since prior corticosteroid therapy Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : Concurrent digoxin control atrial fibrillation allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>